通过孟德尔的随机化和分子对接,生物标志物驱动的机制和前列腺疾病的治疗点通过孟德尔的随机化和分子对接
Luyuan Lu1, Junxiao Shen2, Zujie Chen2
1Department of Surgery, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
概括
这项研究使用门德尔随机化方法将生物标志物与前列腺疾病 (如前列腺炎,良性前列腺增生 (BPH) 和前列腺癌 (PCA)) 联系起来. 确定了新的药物点和准确治疗的重新定位机会.
科学领域:
- 遗传学 是一个遗传学.
- 生物标志物 生物标志物
- 计算生物学 计算生物学
背景情况:
- 前列腺疾病,包括前列腺炎,良性前列腺增生 (BPH) 和前列腺癌 (PCA),构成重大公共卫生挑战.
- 了解生物标志物与这些疾病之间的遗传联系对于开发有效治疗非常重要.
研究的目的:
- 使用孟德尔随机化 (MR) 方法调查各种生物标志物和前列腺疾病之间的因果关系.
- 确定潜在的新型治疗标和药物重定向的前列腺疾病候选人.
主要方法:
- 使用全基因组关联研究 (GWAS) 数据进行了两样本的门德尔随机化 (MR) 分析.
- 检测结果与数据库 (DrugBank),蛋白质与蛋白质相互作用网络,RNA测序和分子对接相结合,以确定治疗点.
主要成果:
- 六种生物标志物证明了前列腺疾病的因果作用:前列腺炎的URK; BPH的GT和TBIL;PCA的UCR,PHOS和BUN.
- 功能整合确定了MPO和TUBB作为BPH的潜在药物标.
- 分子对接建议BPH使用MET和ATP8B1,PCA使用GATA3和ENPP3. 药物重新定位的候选药物包括BPH的甲,PCA的菌素和甲胺.
结论:
- 这项研究提供了将特定生物标志物与前列腺疾病联系起来的遗传证据.
- 确定了BPH和PCA的新药可用标和药物重定向策略,为精准医学方法铺平了道路.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...